Evan Roberts Sells 1,845 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) COO Evan Roberts sold 1,845 shares of the stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $23.81, for a total value of $43,929.45. Following the transaction, the chief operating officer now directly owns 774,807 shares of the company’s stock, valued at approximately $18,448,154.67. This trade represents a 0.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Evan Roberts also recently made the following trade(s):

• On Tuesday, April 8th, Evan Roberts sold 7,233 shares of Phreesia stock. The shares were sold at an average price of $23.85, for a total value of $172,507.05.
• On Tuesday, February 18th, Evan Roberts sold 3,519 shares of Phreesia stock. The shares were sold at an average price of $30.06, for a total value of $105,781.14.
• On Thursday, February 13th, Evan Roberts sold 16,005 shares of Phreesia stock. The shares were sold at an average price of $30.00, for a total transaction of $480,150.00.
• On Monday, January 27th, Evan Roberts sold 10,716 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total transaction of $294,475.68.
• On Tuesday, January 21st, Evan Roberts sold 12,749 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total value of $348,175.19.

Phreesia Stock Up 0.1 %

Shares of NYSE PHR opened at $23.92 on Friday. The firm’s 50 day simple moving average is $26.07 and its two-hundred day simple moving average is $24.29. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53. The stock has a market capitalization of $1.41 billion, a P/E ratio of -16.27 and a beta of 0.82.

Analysts Set New Price Targets

A number of analysts recently issued reports on PHR shares. Citigroup increased their price objective on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. KeyCorp cut their price objective on shares of Phreesia from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Wednesday. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research note on Thursday, March 13th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. Finally, Canaccord Genuity Group increased their price objective on Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $31.33.

Institutional Investors Weigh In On Phreesia

Institutional investors have recently bought and sold shares of the stock. Johnson Financial Group Inc. lifted its position in Phreesia by 381.3% in the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock valued at $28,000 after purchasing an additional 896 shares during the last quarter. R Squared Ltd purchased a new stake in Phreesia during the 4th quarter valued at $30,000. BankPlus Trust Department bought a new stake in Phreesia in the 4th quarter worth $34,000. Quarry LP increased its position in shares of Phreesia by 210.9% in the fourth quarter. Quarry LP now owns 2,835 shares of the company’s stock valued at $71,000 after acquiring an additional 1,923 shares during the period. Finally, Venturi Wealth Management LLC bought a new position in shares of Phreesia during the fourth quarter valued at about $76,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.